Sign in
WithdrawnNo phase

Evaluation of Alcon Ladarvision Wavefront-Guided PRK

Key facts

Who runs it
Walter Reed Army Medical Center
Where
San Diego and Washington D.C., United StatesSee the 2 sites
Trial code
Status
Withdrawn
Type of study
Interventional
Treatments tested
  • Alcon Ladarvision (Wavefront-guided PRK)
Record updated
23 July 2025
Why it stopped
Lack of resources and not because of any concern with the safety or effectiveness of the procedures studied.

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Subjects will be recruited from those active duty soldiers that have requested refractive surgery. Subjects must be eligible for medical care at WRAMC
  • Male or female, of any race, and at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability
  • Manifest refractive spherical equivalent (MSE) of up to -6 diopters (D) at the spectacle plane with refractive cylinder up to 3.00D
  • At least five images must be capturesd in both eyes (dilated) with a pupil size of at least 7mm
  • Manifest refraction and LADARWave™ refractions must be within 1.00 D and the CustomCornea® software must allow for treatment with a 6.5mm minor axis and 9mm ablation zone
  • Best spectacle corrected visual acuity of 20/20 or better in both eyes
  • Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, sa confirmed by clinical records
  • Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements adn have 2 central Keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50D in either meridian; mires should be regular
  • Located it the greater Washington DC Area for a 12-month period
  • Exhibits strong motivation for attending the follow-up visits
  • Consent of the subject's command (active duty) to participate in the study
  • Access to transportation to meet follow-up requirements

Who cannot take part

  • Concurrent topical or systemic medications that may impair healing, including corticosteriods, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or sumatripin
  • Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
  • Medical condition(s), which, in the judgement of the investigator, may impair healing, including but not limited to: collagen vascular diseases and ocular herpes zoster or simplex
  • Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity
  • History of recurrent erosions or epithelial baewsment dystrophy
  • Any physical or mental impairment that would preclude participation in any of the examinations
  • Female subjects who are pregnant, breast feeding or intend to become pregnant during the study
  • Evidence of glaucoma or an intraocular pressure greater than 22mm Hg at baseline
  • Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye

Where in United States

  • Naval Medical CenterSan Diego, United States
  • Walter Reed Army Medical Center, Center For Refractive SurgeryWashington D.C., United States

About the trial

What the trial wants to find out

The purpose of this study is to:

Read full original descriptionShow less

1. determine the safety of wavefront guided PRK 2. evaluate the efficacy of wavefront guided PRK 3. evaluate the differences in visual quality after treatment of wavefront guided PRK

The group in the trial

  • TreatmentTreatment being tested

    Wavefront-guided PRK

    Treatment: Alcon Ladarvision (Wavefront-guided PRK)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 July 2025